1Glorieux FH,Rauch F,Plotkin H,et al. Type V osteogenesis imperfecta: A new form of brittle bone disease [J]. J Bone Miner Res,2000,15:1650-1658.
2Glorieux FH,Ward LM,Rauch F,et al. Osteogenesis imperfecta type Ⅵ: a form of brittle bone disease with a mineralization defect [J]. J Bone Miner Res ,2002,17:30-38.
3Ward LM, Rauch F, Travers R, et al. Osteogenesis imperfecta type Ⅶ:an autosomal recessive form of brittle bone disease [J]. Bone,2002,31:12-18.
4Rauch F,Travers R,Parfitt AM,et al. Static and dynamic bone histomorphometry in children with osteogenesis imperfecta [J]. Bone,2000,26:581-589.
5Boyde A,Travers R,Glorieux FH,et al. The mineralization density of iliac crest bone from children with osteogenesis imperfecta[J]. Calcif Tissue Int, 1999,64:185-190.
6Jones S J,Glorieux FH,Travers R,et al. The microscopic structure of bone in normal children and patients with osteogenesis imperfecta: A survey using backscattered electron imaging [J]. Calcif Tissue Int,1999,64:8-17.
7Cranney A,Wells G,Willan A,et al. Meta-analysis of alendronate for the treatment of postmenopausal women [J]. Endocrine Rev, 2002,23:508-516.
8Kushida K, Shiraki M, Nakamura T, et al. The efficacy of alendronate in reducing the risk for vertebral fracture in Japanese patients with osteoporosis: a randomized, double-blind, active-controlled, double-dummy trial [J]. Curr Ther Res Clin Exp,2002 ,63 :606-620.
9Plotkin H, Rauch F, Bishop NJ, et al. Pamidronate treatment of seve re osteogenesis imperfecta in children under 3 years of age [J]. J Clin Endocrinol Metab,2000,85:1846-1850.
10Shaw N, Boivin C, Crabtree N. Intravenous pamidronate in juvenile osteoporosis[J]. Arch Dis Child ,2000,83:143-145.
